from washingtonpost.com
  CDC Move Raises Impropriety Issue  The Associated Press Thursday, Feb. 17, 2000; 9:25 a.m. EST
  CHICAGO –– The former head of the Centers for Disease Control and Prevention's HIV vaccine unit approved an $8 million grant for research on a vaccine whose manufacturer hired him months later, the Chicago Tribune reported today. He denied any wrongdoing. 
  CDC and VaxGen Inc. officials confirmed Wednesday that Dr. William Heyward played a key role in earmarking $8 million for AIDSVAX trials in October, the Tribune reported. He became VaxGen's vice president for international clinical studies in January. 
  AIDSVAX, the only HIV vaccine undergoing advanced testing, is designed to control HIV infection by generating a type of protein that may be able to prevent the virus from attaching to immune cells. 
  VaxGen and CDC officials said Heyward had cleared his role in the grant allocation with CDC attorneys. 
  In an interview with The Associated Press today, Heyward insisted there was no conflict of interest. 
  Heyward said the CDC funded only six of the 60 research clinics where tests on the vaccine are being conducted. 
  In addition, he said, other CDC officials also approved the agency's participation, and his own decisions on the trials had nothing to do with his impending departure to work for VaxGen, a vaccine maker based in Brisbane, Calif. 
  "I made no decisions myself that dictated where something would be done or not," he said by telephone from his home in Georgia. "My advice was that CDC should be involved in this trial. But I don't care what vaccine it was, I would have said the same thing." 
  Don Francis, VaxGen's president, said he and Heyward had discussed the possibility of Heyward's employment with VaxGen for about two years, but he said they halted negotiations before the October decision to avoid a conflict of interest. 
  The Tribune quoted a CDC spokesman as saying the Atlanta-based health agency's general counsel office is reviewing whether post-employment restrictions policies would apply to the VaxGen matter. 
  Heyward said those restrictions bar him from representing VaxGen on government activities in which he was involved while with the CDC. "I am abiding by that," he said. "I'm playing this strictly by the rules. There've been no breaches." 
  Rep. John Porter, R-Ill., who chairs a House Appropriations subcommittee on biomedical research, said Heyward's role in the AIDSVAX trial grant raises questions of a conflict of interests. 
  whale.to |